FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...
The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.
Capital Market on MSN
Zydus Lifesciences gains after launching denosumab biosimilar
Denosumab is a monoclonal antibody with several indications related to bone health, primarily used in the treatment of ...
Patel, Managing Director, Zydus Lifesciences, said With Denosumab 120 mg SC, we aim to bring access, affordability of medication in cancer patients needing critical care. This will help patients to ...
Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback